• Blogroll

  • Blogpennystocks Book Store
  • Go Haceem!
  • IndoDONKEY
  • Mira Iskarnita

Heart disease is, unfortunately, a growth industry, Three percent of baby boomers currently have heart disease and that number is expected to grow 10-15 percent within that demographic over the next 10 years. That’s more than 500,000 new cases annually for what remains the number one killer in the US of both men and women. Healthcare costs associated with heart disease already exceed $23 billion annually.

MIV Therapeutics Inc. (Symbol: MIVT) is an advanced stage, research and development company pursuing the commercialization of the next generation of fully biocompatible coatings for stents and other medical devices with the intent of providing healing solutions for cardiovascular disease and other conditions. In collaboration with the University of British Columbia (UBC), the Company has developed unique coating technologies that utilize Hydroxyapatite (HAp) for application on medical devices and drug delivery systems.

MIVT has a strategic alliance with the University of British Columbia (UBC), where it has licensed from the university worldwide rights to technologies for coating stents and other medical devices with HAp. This coating enhances the biocompatibility of implanted devices since it is a material that is found in the body as the main constituent of bone.

MIVT’s technology is considered to be suitable for broad applications in cardiovascular and non-vascular drug/device combination products. The Company’s goal is to continue on its path of success and diversify its portfolio to capitalize on these potential applications, accessing the $200 billion market of combination drug/device products.

MIVT’s current product portfolio encompasses the following preclinical development projects:

• HAp-nano-film coating technology. The Company’s lead product in development is an HAp-coated coronary stent with a nano-film coating. HAp is naturally found in bone and tooth enamel and is rapidly integrated into the human body. As such, it may inhibit a variety of adverse and inflammatory reactions and potentially help reduce restenosis, a recurrence of CAD following angioplasty. It is also believed that HAp-coated cardiovascular stents will not trigger late adverse thrombogenic reactions.

• Drug-eluting stents. The Company is expected to enter the drug-eluting stent market by using a thicker coating of HAp loaded with a suitable drug, i.e. anti-inflammatory. The technology has applications in cardiovascular and non-cardiovascular drug/device combination products, including peripheral stents, biodegradable implants, gene therapy, and delivery systems for release of chemotherapeutic agents.

Recently there was a spike in the volume which, I must say, really intrigued me. The price has jumped up from $0.35/share to around $0.55/share. It went down a bit, then it shot up to $0.60/share. Could it be because Ernest C. Schloter, a senior analyst with Investrend affiliate SISM Research and a four star analyst according to StarMine, has reiterated his “Buy/4″ Rating and $2.50 12-month Target Valuation for MIV Therapeutics, Inc. in a Research Note?

Here are some of the comments which I have heard about them:

“The drug-eluting stent market grew from zero to $5.3 billion in three years and has captured 85% of the US stent market. To date, more than nine million DES devices have been inserted. In 2005, about 1.5 million patients were implanted with drug-eluting stents in the US alone…”

“Despite a stock price increase of more than 50% since last Wednesday, in our view, MIVT, at a market cap of only $35 million, is still massively undervalued… MIV Therapeutics is paying SISM Research $2,250 per month over a two-year period solely to ensure independent coverage.”

Hmm pretty interesting, don’t you think? I’m always fond of biotech stocks, regardless of whether they’re traded at a ridiculously low price or amazingly high price. This one happens to be traded a ridiculously low price and even a lot of people think of this one is undervalued. Well…We’ll see what’s going to happen with this one in the next 3-6 months.

Source: mivtherapeutics.com

Quote of the Day:
Foreign Aid: Taxing poor people in rich countries for the benefit of rich people in poor countries. – Bernard Rosenberg

I’ve been watching this stock in the past 2 months and I have to tell you, I made right decision to add this one to my “stock-watch” list..

Cambridge Heart Inc. (Symbol: CAMH) is a healthcare company, engaged in the research, development, and commercialization of products for the non-invasive diagnosis of cardiac disease. According to the information on their website, Cambridge Heart’s products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans.

Above is the graph of their stock perfomance in the past 3 months. When I started watching them (which was early in January), the stock was traded at $0.72/share. And now? It’s $1.45/share.

Even though their revenue has declined by 21.9% since last year ($1,089,200 in Q4 2005 vs. $1,394,800 in Q4 2004), but I firmly believe this company is going to be doing well this year since they’ve got good products to sell.

It is not easy to find a company who develop and sell good products, and whose stock is traded less than $5/share. I was pretty luck to come accross this one when I was doing my weekly stock research.

Quote of the Day:
It’s important to be able to make decisions without complete or perfect information. Things are almost never clear on Wall Street, or when they are, then it’s too late to profit from them. – Peter Lynch

Biophan Technologies Inc. (Symbol: BIPH) develops technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. They also develop surgical devices suc as catheters and guidewires, implanted medical systems such as pacemakers, and other devices such as stents to be safely and effectively imaged under MRI. Currently Biophan and its licensors hold a total of 144 US patents, licenses, or applications.

They recently just acquired MYOTECH, LLC – who is currently developing the first generation of MYO-VAD, a device designed to quickly restore cardiac output in patients suffering from many forms of heart failure (Read here). They velieve that the MYO-VAD devices has a great potential to generate $100 million in annual revenue for Biophan in approximately five years (Heh..Not too bad!)

Their outline of technological and financial strategy was recently published on Medical Technology Business Europe (Read here) – which I think you have to read before deciding whether to invest your money in this company or not.

Currently, they’re traded at $1.59/share. Their were once traded as high as $3.50/share. Judging from how crazy they fluctuate within the past 12 months, I’ll have to say they’re only good as a long-term investment.

Their technologies are still in testing phase. They haven’t started selling their products yet (so don’t expect to see their price/share go up through the roof anytime soon). However, if you want to invest in them, right now is definitely a good time to invest.

Recently, I’ve started paying more attention to bio-tech stocks. I realized that most of these biotech companies are not making a lot of money (yet) since most of them are still trying to perfect their technologies. I guess for the next few postings, you can expect to see a lot about the bio-tech companies

Quote of the Day:
If you can run one business well, you can run any business well. – Richard Branson

Came accross this company when I did my research last weekend. They used to be traded as high as $0.50/share. Then it’s been going down drastically and currently it’s traded at $0.05/share. I’m not really sure if the stock is going to perform well sometime in the near future, but looks like the company is doing pretty well. Thought I’d post it here maybe someone will be interested in invest in this company since the price/share is really low.

About the company?
Austin Medical Technologies delivers “DIRECT” from the manufacturer to the Surgeon, the only technology based, “Single Source Supply Solution” for custom sterile surgery trays made up of 80% of all disposable surgical devices utilized in surgery. Currently the company has contracted with 200 eye surgery centers including the 2 largest eye surgery centers in the USA. The market for custom sterile surgery trays is a $2.1 Billion market here in the USA.

Austin Medical is dedicated exclusively to the Ambulatory Surgery Center (ASC) market. Ambulatory Surgery Centers (ASC), also called outpatient surgery, and same-day surgery, refers to surgical procedures which are complex enough to require a dedicated operating room and specially trained staff, but do not require an overnight stay. According to 1996 U.S. government statistics, ambulatory surgery centers account for 31 million or 44% of the total surgeries performed in the United States. Five million surgeries were performed on eyes. New surgical techniques such as laser surgery allow procedures to be done more quickly and/or with less surgical trauma.

Under the brand name eyeDirecti, Austin Medical is initially focused on Ophthalmology owned and operated surgery centers which is the fastest growing segment of the ASC market, growing by 25% per annum, consisting of 2,500 practices with 15,000 surgeons performing over 5 million surgical procedures annually at a supply cost of $400,000,000 per year. (Source: Yahoo News)

Recently they just had a press release saying that they have just added 14 new customers in the 3rd quarter, adding new sales of $1.1 million over the contracted period. And one more thing, Austin Medical is positioned to capture $40,000,000 (10%) of this $400,000,000 market within the next 4 years. As I’ve said before, I’m pretty sceptical if this stock is going to perform well, but looks like if you look at the company profile and the industry, the company is surely going to be doing well in the future. We’ll see about this. I’m going to be watching this company very closely for the next few months.

Quote of the Day:
If we find a company we like, the level of the market will not really impact our decisions. We will decide company by company. We spend essentially no time thinking about macroeconomic factors. – Warren Buffett

• Search



• Categories

  • Apparel/Accessories
  • Biotechnology & Drugs
  • Business Services
  • Chemical Manufacturing
  • Communication Services
  • Communications Equipment
  • Computer Hardware
  • Computer Services
  • Electronic Instr. & Controls
  • Energy
  • Medical Equipment & Supplies
  • Nanotechnology
  • Oil & Gas Operations
  • Other
  • Recreational Products
  • Retail
  • Security Systems & Services
  • Software & Programming

• Archives

  • June 2009
  • December 2008
  • November 2008
  • December 2007
  • October 2007
  • August 2007
  • July 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • December 2006
  • November 2006
  • October 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • February 2006
  • December 2005
  • November 2005
  • May 2005
  • April 2005
  • March 2005
  • February 2005
  • January 2005
  • December 2004
  • November 2004
  • October 2004
  • September 2004